Bottom Line

Entyvio is an integrin receptor antagonist that may be used to treat moderate to severe ulcerative colitis or Crohn's disease. It specifically targets the gut rather than the entire body, which may reduce its systemic (whole-body) immunosuppressive effects, but it is still likely to increase an individual's risk of infection.